Trial Profile

Cellular Pharmacology of Tenofovir and Emtricitabine for HIV Prophylaxis (Cell Prep)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
Indications HIV infections
Focus Pharmacokinetics; Therapeutic Use
Acronyms Cell Prep

Most Recent Events

29 Aug 2016 Results of this and other four studies published in the Antimicrobial Agents and Chemotherapy (2016).
27 Jun 2016 Results of analysis of endogenous deoxynucleoside triphosphate pool (n=40) published in the Antimicrobial Agents and Chemotherapy
20 Nov 2013 Planned end date changed from 1 Aug 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com